Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE

Conclusions. Grazoprevir and elbasvir with ribavirin for 12 weeks maintained HCV suppression for at least 24 weeks posttherapy without late relapses. Baseline resistance-associated variants (RAVs) stably reappeared at relapse in all 3 patients with virologic failure. NS5A_RAVs emerging at relapse persisted for the full 24-week follow-up period. If confirmed, this finding could complicate retreatment of the small number of patients failing regimens containing an NS5A inhibitor.
Clinical Trials Registration. NCT02105454.

Source: Clinical Infectious Diseases - December 14, 2015 Category: Infectious Diseases Authors: Buti, M., Gordon, S. C., Zuckerman, E., Lawitz, E., Calleja, J. L., Hofer, H., Gilbert, C., Palcza, J., Howe, A. Y. M., DiNubile, M. J., Robertson, M. N., Wahl, J., Barr, E., Forns, X. Tags: ARTICLES AND COMMENTARIES Source Type: research